Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

NEW YORK : Pfizer reported better than expected quarterly profits today behind cost cuts and growth in some non-Covid-related ...